Nichi-Iko Pharmaceutical: The University of Tokyo, RIKEN, NichiIko & Daiichi Sankyo ink collaborative R&D on nafamostat inhalation formulation to treat COVID19
The University of Tokyo, RIKEN, Nichi─Iko Pharmaceutical Co., Ltd. and Daiichi Sankyo Company, Limited have reached a basic agreement on collaborative
Read full article »
President & CEO
Yuichi Tamura
Nichi-Iko Pharmaceutical engages in manufacturing and commercializing prescription drugs issued by hospitals, clinics, pharmacies and drug stores.
Read more